The answer to this question depends on the patient's molecular diagnostics and prior therapy. I'll assume FOLFOX/XELOX-bev. If KRAS WT, I'll assume followed by FOLFIRI-EGFRi. If the patient is MSI-H, I would strongly recommend immunotherapy with pembrolizumab based on Le et al, NEJM. If MSS and you ...